Immodulon Therapeutics announces new appointments to Board of Directors

LONDON, UK – Wednesday 10 June, 2015 – Immodulon Therapeutics, a privately held, late-stage biopharmaceutical company focused on immuno-oncology, has made two new senior appointments to its Board of Directors to support its continued growth.

Anthony Bolton, one of the UK’s best known and most successful investment fund managers and Sir Simon Robertson, deputy chairman of HSBC will join Immodulon as non-executive directors with immediate effect.

Immodulon Chairman, Charles Akle commented:

“Anthony and Simon will bring a wealth of commercial experience and insight to the Immodulon Board as we focus on our future development and progress towards Phase III of our lead product, IMM-101, in pancreatic cancer. We look forward to benefitting from their experience and counsel.”


Immodulon Therapeutics is a leading biopharmaceutical company advancing new immunotherapy treatments, an approach now recognised as the biggest breakthrough in cancer since chemotherapy. Immodulon’s lead product, IMM-101, has shown clinically significant improvements in survival in metastatic pancreatic cancer without increasing toxicity.

Anthony Bolton joined Fidelity in 1979. He has managed several Fidelity funds including the Fidelity Special Situations which he ran for 28 years up to 2007. During this time the fund became the largest unit trust in the UK and achieved annual growth of almost 20%. More recently, he wrote an investment book 'Investing Against the Tide' and managed Fidelity China Special Situations PLC whilst based in Hong Kong for 4 years.

Although he retired from fund management in 2014 he remains a board member and adviser at Fidelity as well as a trustee of its charitable foundations.

Sir Simon Robertson joined the board of HSBC in 2006 and has served on a number of board committees. He has an extensive background in international corporate advisory work and a wealth of experience in mergers and acquisitions and financial markets. His international experience includes working in France, Germany, the UK and the USA. He was knighted in the 2010 Queen’s birthday honours list in recognition of his services to business.

He is the founding member of Simon Robertson Associates LLP; a non-executive director of Berry Bros & Rudd Limited, The Economist Newspaper Limited and Troy Asset Management; and a trustee of the Eden Project Trust and of the Royal Opera House Endowment Fund.

Sir Simon’s previous roles include non-executive chairman of Rolls-Royce Holdings plc; non-executive director of NewShore Partners Limited and of Royal Opera House, Covent Garden Limited; Managing Director of Goldman Sachs International and Chairman of Dresdner Kleinwort Benson.